NEW YORK (GenomeWeb) – Quest Diagnostics and Inserm, the French National Institute of Health and Medical Research, have launched an initiative called BRCA Share to provide open access to genetic variant data for the BRCA1 and BRCA2 genes, and have signed on LabCorp, Quest's main competitor in the US clinical lab market, as their first participant.

The goal of the program is to accelerate research into BRCA mutations, in particular variants of uncertain significance, in order to improve variant interpretation by clinical diagnostic laboratories.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sponsored by

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers. 

Sponsored by
Cofactor Genomics

This webinar will discuss the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.